IP Library Granted Patent US 9,403,783
Granted Patent B2
US 9,403,783 · App. 13/084,612 · Granted Aug 2, 2016

Methods for producing viloxazine salts and novel polymorphs thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,403,783
App. No.
13/084,612
Granted
Aug 2, 2016
Kind
B2
Abstract

Provided here are methods of manufacture of viloxazine and its various salts, as well as viloxazine-related compounds, such as novel intermediate reaction products and polymorphs thereof. In particular, the methods provide a substantially pure API of viloxazine HCl while avoiding undesirable impurities. The methods further provide for separating, identifying, and characterizing novel polymorphs of viloxazine. Further provided are methods for synthesis and identification and characterization of novel intermediates of viloxazine, as well as for some important metabolites and precursors of metabolites of viloxazine.

Claims (13)

1. A method of manufacturing viloxazine or a pharmaceutically acceptable salt thereof, the method comprising:

(a) reacting a compound of formula

with N-benzyl-aminoethanol to form a diol compound of formula

(b) contacting said diol compound in a solvent system with a base to generate a basic system;

(c) contacting the basic system with a cyclization agent to produce a 2-substituted morpholine compound having the following formula:

wherein Et is an ethyl group and Bn is a benzyl group; and,

(d) removing the benzyl group from the 2-substituted morpholine compound to generate viloxazine, or a pharmaceutically acceptable salt thereof, with less than 2.5 ppm of an impurity selected from the group consisting of epichlorohydrin, and 1-(2-ethoxyphenoxy)-2,3-epoxypropane.

2. The method of claim 1 wherein a phase transfer catalyst is utilized in step (c).

3. The method according to claim 1 , wherein the solvent system is a liquid-liquid biphasic system or a monophasic liquid system.

4. The method of claim 1 , wherein the base is a solid.

5. The method according to claim 3 , wherein the monophasic liquid system comprises toluene.

6. The method according to claim 4 , wherein said base is sodium hydroxide.

7. The method according to claim 2 , wherein said phase transfer catalyst is benzyltriethylammonium chloride.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Nov 30, 2017
From: U.S. BANK NATIONAL ASSOCIATION
To: SUPERNUS PHARMACEUTICALS, INC.
Reel/Frame 044552/0694 →
SECURITY AGREEMENT Recorded Jun 7, 2013
From: SUPERNUS PHARMACEUTICALS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 030571/0679 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2012
From: DAIN, DAVID
To: SUPERNUS PHARMACEUTICALS, INC.
Reel/Frame 029354/0305 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2012
From: LIANG, LIKAN; BHATT, PADMANABH P.; DAIN, DAVID; TAQUET, JEAN-PHILIPPE; PECHENOV, ALEKSANDR; TCHESNOKOV, ALEXEI; MARIAUX, REYNOLD
To: SUPERNUS PHARMACEUTICALS, INC.
Reel/Frame 028179/0048 →